Scott P. Myrand

PD98059 Is an Equipotent Antagonist of the Aryl Hydrocarbon Receptor and Inhibitor of Mitogen-Activated Protein Kinase Kinase

John J. Reiners, Jing‐Yu Lee, Russell E. Clift et al. · Molecular Pharmacology · 1998 · 146 citations

High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes

Michael Shi, Scott P. Myrand, M. R. Bleavins et al. · Molecular Pathology · 1999 · 78 citations · Full text

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

Giorgio V. Scagliotti, Jin Hyoung Kang, David C. Smith et al. · Investigational New Drugs · 2016 · 68 citations

Phase Ii Evaluation, Oncology, Medicine +6

Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial

M. Nicolson, Dean A. Fennell, David Ferry et al. · Journal of Thoracic Oncology · 2013 · 60 citations · Full text

Limited influence of <i>UGT1A1*28</i> and no effect of <i>UGT2B7*2</i> polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes

Vincent Peterkin, Jonathan Bauman, Theunis C. Goosen et al. · British Journal of Clinical Pharmacology · 2007 · 55 citations · Full text